title: Update on the Development of Anti-Viral Agents Against Hepatitis C.
abstract: Hepatitis C virus (HCV) infects nearly 170 million people worldwide and causes chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The search for a drug regimen that maximizes efficacy and minimizes side effects is quickly evolving. This review will discuss a wide range of drug targets currently in all phases of development for the treatment of HCV. Direct data from agents in phase III/IV clinical trials will be presented, along with reported side-effect profiles. The mechanism of action of all treatments and resistance issues are highlighted. Special attention is given to available trial data supporting interferon-free treatment regimens. HCV has become an increasingly important public health concern, and it is important for physicians to stay up to date on the rapidly growing novel therapeutic options.
authors.affiliation: Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA02215.
authors.forename: Kristin L
authors.initials: KL
authors.lastname: Macarthur
authors.affiliation: Faculty of Medicine, Osijek, Croatia.
authors.forename: Robert
authors.initials: R
authors.lastname: Smolic
authors.affiliation: Faculty of Medicine, Osijek, Croatia.
authors.forename: Martina V
authors.initials: MV
authors.lastname: Smolic
authors.affiliation: Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA.
authors.forename: Catherine H
authors.initials: CH
authors.lastname: Wu
authors.affiliation: Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA.
authors.forename: George Y
authors.initials: GY
authors.lastname: Wu
keywords: Drug; HCV; Polymerase; Protease; Triple therapy